Special Issue "Management of Atopic Dermatitis"
Deadline for manuscript submissions: 30 September 2020.
Interests: psoriasis; hidradenitis suppurativa; atopic dermatitis; immune-mediated skin diseases; pharmacogenetics; biotechnological therapies
Childhood and adult atopic dermatitis (AD) is a chronic inflammatory skin condition with variable clinical phenotypes, partly related to age, ethnicity, and disease severity, that causes a significant psychological and financial impact on patients, families and society. A combination of genetic and environmental factors, which induce skin barrier dysfunction; abnormal immune activation of Th2 and Th22; varying degrees of Th1 and Th17 axis dysregulation; and skin microbiota dysbiosis, together with a strong psychosomatic profile, may all influence therapeutic strategies. AD clinical and molecular heterogeneity highlights the unmet need for effective therapeutic options against more than one immune axis pathways. Published data, medical training, individual experience, and institutional norms mostly drive the published AD treatment guidelines. Therapeutic goals require a multistep approach to reduce pruritus and establish disease control primarily based on disease severity, patient’s age, comorbidities, compliance, and costs. Topical and systemic drugs in development are innumerable and schematically divided into intra or extracellular agents. Ongoing randomized clinical trials demonstrate the efficacy and safety of several antagonist new drugs acting on objective and subjective disease parameters and on quality of life. However, studies on real-life experience are expected to include more information since patients from clinical trials do not act typically. This Issue examines the pathophysiology, epidemiology, heterogeneous clinical presentation, burden, diagnosis, and new topical and systemic emerging treatments of AD.
Prof. Luca Bianchi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- atopic dermatitis
- emerging therapies
- quality of life